Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA83279
Max Phase: Preclinical
Molecular Formula: C26H27N3O
Molecular Weight: 397.52
Molecule Type: Small molecule
Associated Items:
ID: ALA83279
Max Phase: Preclinical
Molecular Formula: C26H27N3O
Molecular Weight: 397.52
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: c1ccc(-n2cnc3cc(-c4ccc(OCCN5CCCCC5)cc4)ccc32)cc1
Standard InChI: InChI=1S/C26H27N3O/c1-3-7-23(8-4-1)29-20-27-25-19-22(11-14-26(25)29)21-9-12-24(13-10-21)30-18-17-28-15-5-2-6-16-28/h1,3-4,7-14,19-20H,2,5-6,15-18H2
Standard InChI Key: PNGUVNHPACPGIY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 397.52 | Molecular Weight (Monoisotopic): 397.2154 | AlogP: 5.56 | #Rotatable Bonds: 6 |
Polar Surface Area: 30.29 | Molecular Species: BASE | HBA: 4 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 8.83 | CX LogP: 5.50 | CX LogD: 4.06 |
Aromatic Rings: 4 | Heavy Atoms: 30 | QED Weighted: 0.43 | Np Likeness Score: -1.34 |
1. Bilodeau MT, Cunningham AM, Koester TJ, Ciecko PA, Coll KE, Huckle WR, Hungate RW, Kendall RL, McFall RC, Mao X, Rutledge RZ, Thomas KA.. (2003) Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR., 13 (15): [PMID:12852948] [10.1016/s0960-894x(03)00485-2] |
Source(1):